a double-blind clinical comparison in patients with osteoarthritis showed the sustained-release preparation ( 1 g daily ) to be equivalent in efficacy to conventional naproxen capsules ( 500 mg twice daily ) but to have a significantly lower incidence of gastrointestinal side-effects .
C0029408
osteoarthritis
C0027396
naproxen